Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2017 Nov 13;17(1):84–95. doi: 10.1158/1535-7163.MCT-17-0705

Figure 4. PLX8394 prevents significant paradoxical ERK1/2 activation in WT BRAF melanomas.

Figure 4

A. Western blot analysis of WT/WT melanoma cell lines after treatment with DMSO, vemurafenib (1 μM), PLX8394 (0.5 μM) or trametinib (50 nM) for 48 hours. B. Quantitation of the normalized pERK1/2 signal from A. C. As in Fig 2B, except that two different WT/WT melanoma cells were used to form xenografts and were processed/treated in the ex vivo explant system. Western blot analysis of lysates prepared from explants treated with DMSO, vemurafenib or PLX8394 after 48 hours. Densitometry results of pERK1/2 to ERK2 are indicated. D. WT/WT patient sample explants (TJU-MEL-29) were treated as in A for 48 hours. Densitometry values are shown.